Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | SCD | O00767 | 6/20 | 0.34 |
| ▸ | IKBKB | O14920 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.33 |
| ▸ | MYC | P01106 | 2/20 | 0.33 |
| ▸ | WDR5 | P61964 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2540906 | 0.88 | GPR119 (0.45) | SMN1; SMN2PDE4B | |
| SCHEMBL1549862 | 0.86 | GPR119 (0.43) | — | |
| SCHEMBL2542089 | 0.84 | GPR119 (0.34) | SMN1; SMN2RAB9ASCDIKBKB | |
| SCHEMBL1550677 | 0.84 | GAA (0.40) | KMT2ASMN1; SMN2RAB9ACNR1GAA | |
| SCHEMBL2546749 | 0.83 | FPR2 (0.37) | SMN1; SMN2CNR1SCD | |
| SCHEMBL14237487 | 0.81 | GPR119 (0.45) | SMN1; SMN2PDE4B | |
| SCHEMBL1549998 | 0.80 | ALDH1A1 (0.41) | KMT2ASMN1; SMN2SCDTDP1 | |
| SCHEMBL1551079 | 0.80 | GPR119 (0.46) | — | |
| SCHEMBL2539976 | 0.78 | GPR119 (0.46) | SMN1; SMN2PDE4B | |
| SCHEMBL14237660 | 0.78 | JAK3 (0.36) | KMT2ASMN1; SMN2SCDPDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130131074-A1 | PYRIDONE AND PYRIDAZONE ANALOGUES AS GPR119 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-05-23 | — | — | US | disclosed |
| US-8372837-B2 | Pyridone and pyridazone analogues as GPR119 modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-02-12 | — | — | US | disclosed |
| EP-2313395-B1 | PYRIDONE AND PYRIDAZONE ANALOGUES AS GPR119 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2012-12-19 | — | — | EP | disclosed |
| US-20110263548-A1 | PYRIDONE AND PYRIDAZONE ANALOGUES AS GPR119 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131074-A1 | PYRIDONE AND PYRIDAZONE ANALOGUES AS GPR119 MODULATORS | GPR119, GPR4, GPR3 | KMT2A 3211/4885SMN1; SMN2 2820/4885RAB9A 1722/4885 |
| US-20110263548-A1 | PYRIDONE AND PYRIDAZONE ANALOGUES AS GPR119 MODULATORS | GPR119, GPR4, GPR3 | KMT2A 3266/4885SMN1; SMN2 2854/4885RAB9A 1599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.